Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05741502 · ClinicalTrials.gov registry record · Phase 4
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
A Phase 4 study, sponsored by Ohio State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT05741502 is a Phase 4 study that was terminated before completion, run by Ohio State University. The registered enrollment target is 5 participants.
The verdict
NCT05741502, a Phase 4 study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The specific aim of this protocol is to compare Clozapine treatment vs Non-Clozapine antipsychotic treatment in a population of treatment-refractory individuals with schizophrenia. Specifically, it is to test if Clozapine leads to a decrease in levels of inflammatory markers, namely interleukin-6 but with an exploratory view of other markers. Clozapine has superior efficacy and is the only medication approved for treatment-refractory schizophrenia in addition to decreasing the risk of suicidal behavior as well. It is unclear why Clozapine has increased efficacy from a mechanistic viewpoint. We will look at the role of inflammatory markers and assess them 1x along with rating scales for psychosis and suicidality, the other entities which Clozapine has been shown to improve.
Interventions
- DRUG Clozapine
- DRUG Antipsychotics,Other (non-Clozapine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2026-01-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05741502
The ClinicalTrials.gov registry entry for NCT05741502 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clozapine is the first listed.
NCT05741502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05741502 about?
NCT05741502 is a clinical study titled "An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine". The specific aim of this protocol is to compare Clozapine treatment vs Non-Clozapine antipsychotic treatment in a population of treatment-refractory individuals with schizophrenia. Specifically, it is to test if Clozapine leads to a decrease in levels of inflammatory markers, namely interleukin-6 bu...
What is the current status of trial NCT05741502?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2023-08-16. Estimated completion is 2026-01-23.
What interventions are being tested in trial NCT05741502?
The interventions under investigation include: Clozapine (DRUG), Antipsychotics,Other (non-Clozapine) (DRUG).
Who is sponsoring clinical trial NCT05741502?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.